Biotop-report 2012

17

BioTOPics 44 | May 2012 

BioTOP-Report

nanoPET Pharma GmbH

nanoPET is a biopharmaceutical company 

specialized on R&D, manufacturing and mar-

keting of innovative drug substances for 

Diagnostic Imaging. We focus on relevant 

cardiovascular, oncological and neurological 

indications as well as on regenerative medi-

cine. Nanotechnology is a key element of our 

business. We operate in three major areas.

The first nanoparticular tracers for clini-

cal PET: nanoPET prepares the clinical devel-

opment of its patented technology platform: 

inorganic nanoparticular tracers for cell- and 

molecular-specific positron emission tomog-

raphy (PET).

Viscover™ imaging agents – a landmark 

in small animal imaging: As animal imag-

ing is rapidly gaining relevance in pharma-

ceutical research, we are delighted to offer 

you an exciting portfolio of specialized pre-

clinical imaging agents covering the princi-

pal imaging modalities (MRI, CT, Ultrasound, 

Optical Imaging, SPECT & PET). Get a 

detailed insight into our product portfolio 

and download a free copy of our imaging 

guide on www.viscover.com

Consulting and Service tailored to your 

needs: As a technology and service provider, 

we offer our expertise to biopharmaceutical 

companies and imaging equipment manu-

facturers. Our customers benefit from the 

long-standing industry expertise our team 

has attained in the pharmaceutical 

research & development.

Address 

nanoPET Pharma GmbH

Robert-Koch-Platz 4

10115 Berlin · Germany

Contact

Dr. Andreas Briel · CEO

Phone  [phone]

[e-mail]

www.nanopet-pharma.com

Evestra GmbH

Evestra GmbH, founded in July 2008, is a 

fully owned subsidiary of Evestra Inc. locat-

ed in San Antonio Texas. Evestra GmbH 

serves as the development and commercial-

ization center for Europe and ROW. Evestra’s 

mission is to develop and commercialize 

steroid-based female healthcare products. 

The development strategy of the company 

includes product ideas with known com-

pounds as well as New Chemical Entities. 

Evestra is conducting research and product 

development in a number of in-demand, but 

as yet unmet, medical need areas of wom-

en’s health such as hormonal-dependent 

breast cancer and endometriosis. The com-

pany is also pursuing different projects in 

fertility control, e.g. a new estrogen for oral 

contraception, with superior pharmacologi-

cal properties compared to the standard 

drug ethinyl estradiol. 

Several patents on new composition of mat-

ter, new technical processes and use patents 

have been filed during the last three years 

and support the strong intellectually prop-

erty position. Evestra is concentrating on 

R&D and will seek more partners for com-

mercialization. 

More detailed information can be found on 

our web side.

Address 

Evestra GmbH

Britzer Straße 26

12439 Berlin · Germany

EU Contact

Prof. Klaus Nickisch · Managing Director 

Phone [phone]

[e-mail]

www.evestra.com

---

18

BioTOPics 44 | May 2012 

BioTOP-Report

Biotech Parks

The BioCampus Network Berlin-Brandenburg

Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements 

of every company. This geographic concentration of specific biotech parks is unique in Germany and probably 

in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. 

More than half of the 215 companies are currently utilizing the infrastructure of a publicly or privately man-

aged park. In addition, the young companies benefit from the closeness to science and the permanent contact 

and exchange.

berlinbiotechpark

In the very heart of Berlin

berlinbiotechpark is located on a 86,000 sq.m. site in the very 

heart of Berlin, currently offering a total of approx. 57,000 sq.m. 

of office, laboratory and production space, with a building poten-

tial for another 45,000 sq.m. of rental area.

The site, which is home to 32 Biotech/Pharma/Service Compa-

nies is supplied with a complete range of media for laboratory 

and production purposes, with production steam with possibility 

to upgrade to HP steam, power supply, compressed-air, nitrogen 

and other inert gases, cooling water, DI-water, with possibility 

to upgrade to aqua purificata and water for injection, all being 

provided at favorable rates. 

The infrastructure includes a canteen and conference facilities as 

well as works security and waste disposal services. It is rounded 

off by production-related  services such as plant engineers and 

laboratory technicians, industrial safety engineers, a medical 

service as well as best-buy services and communication services. 

Offering flexible growth potential, production-orientated media 

equipment and comprehensive industrial-specific services and 

infrastructure, berlinbiotechpark is particularly attractive for 

growing internationally orientated technology companies. Fur-

thermore, it offers a permanent base in Berlin for developing 

companies that have outgrown the size allowed by their limited 

start-up funding. The inner-city location and the excellent public 

transport guarantee short ways to all scientific institutions and 

hospitals of the city.

berlinbiotechpark

Tegeler Weg 33 · Max-Dohrn-Straße 8-10 · 10589 Berlin

Phone [phone] · Fax [phone]

[e-mail] · www.berlinbiotechpark.de

Contact: Ingo Schneemann

Biotech Campus Potsdam

Research on the Waterfront 

Just a few minutes away from Potsdam’s central railway station 

in the direction of Caputh, Biotech Campus Potsdam is located 

on the Hermannswerder peninsula in the river Havel. It is owned 

and operated by Biotech Campus Potsdam GmbH, a fully owned 

subsidiary of the Investment Bank of the State of Brandenburg.

The biotechnology center is housed in four buildings dating from 

around 1900 and one modern complex and offers a total of 

11,400 sq.m. of laboratory, office, greenhouse and storage space. 

With such a large facility at its disposal, it offers biotechnology 

companies an ideal environment for successful operations. All 

labs are approved as S1 laboratories and meet the building re-

quirements for approval as S2 labs. The Hermannswerder site 

also includes an S3 laboratory as a special resource. The beautiful, 

park-like setting of the peninsula offers an excellent environment 

for research activities. The island hotel and a conference center 

are located directly next to the campus. 

---